PL3137094T3 - Leczenie i profilaktyka choroby alzheimera (ad) - Google Patents

Leczenie i profilaktyka choroby alzheimera (ad)

Info

Publication number
PL3137094T3
PL3137094T3 PL15720060.1T PL15720060T PL3137094T3 PL 3137094 T3 PL3137094 T3 PL 3137094T3 PL 15720060 T PL15720060 T PL 15720060T PL 3137094 T3 PL3137094 T3 PL 3137094T3
Authority
PL
Poland
Prior art keywords
alzheimer
disease
prevention
treatment
Prior art date
Application number
PL15720060.1T
Other languages
English (en)
Inventor
Markus Mandler
Achim Schneeberger
Wolfgang Zauner
Arne Von Bonin
Frank Mattner
Walter Schmidt
Original Assignee
Advantage Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advantage Therapeutics, Inc. filed Critical Advantage Therapeutics, Inc.
Publication of PL3137094T3 publication Critical patent/PL3137094T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
PL15720060.1T 2014-04-29 2015-04-29 Leczenie i profilaktyka choroby alzheimera (ad) PL3137094T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14166388 2014-04-29
EP14166355 2014-04-29
PCT/EP2015/059341 WO2015165968A1 (en) 2014-04-29 2015-04-29 Treatment and prevention of alzheimer's disease (ad)

Publications (1)

Publication Number Publication Date
PL3137094T3 true PL3137094T3 (pl) 2023-03-13

Family

ID=53039897

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15720060.1T PL3137094T3 (pl) 2014-04-29 2015-04-29 Leczenie i profilaktyka choroby alzheimera (ad)

Country Status (12)

Country Link
US (3) US11065273B2 (pl)
EP (2) EP3137094B1 (pl)
JP (1) JP2017515812A (pl)
KR (1) KR102506460B1 (pl)
CN (1) CN106659736A (pl)
AU (1) AU2015254665A1 (pl)
CA (1) CA2946931A1 (pl)
DK (1) DK3137094T3 (pl)
FI (1) FI3137094T3 (pl)
PL (1) PL3137094T3 (pl)
PT (1) PT3137094T (pl)
WO (1) WO2015165968A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6692755B2 (ja) * 2014-04-29 2020-05-13 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ アルツハイマー病（ａｄ）の処置および予防
CA2946929A1 (en) * 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
WO2015165968A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016327A1 (en) * 1993-01-14 1994-07-21 Pollard Harvey B Methods and compositions for blocking amyloid protein ion channels
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
MXPA04010255A (es) * 2002-04-19 2008-03-04 Univ Toronto Metodos inmunologicos y composiciones para el tratamiento de la enfermedad de alzheimier.
AT413946B (de) 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
WO2009105641A2 (en) 2008-02-20 2009-08-27 New York University Preventing and treating amyloid-beta deposition by stimulation of innate immunity
AT506819B1 (de) 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
AT506820B1 (de) 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
EP2145898A1 (en) * 2008-07-15 2010-01-20 CHIESI FARMACEUTICI S.p.A. Anti-amyloid immunogenic compositions, methods and uses
MA34084B1 (fr) 2010-03-29 2013-03-05 Novartis Ag Composition comprenant le peptide amyloïde bêta 1-6 couplé à une particule de type virus et un adjuvant
GB201101331D0 (en) 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
CA2946929A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
WO2015165968A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
JP6692755B2 (ja) 2014-04-29 2020-05-13 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ アルツハイマー病（ａｄ）の処置および予防

Also Published As

Publication number Publication date
WO2015165968A1 (en) 2015-11-05
KR20160145821A (ko) 2016-12-20
EP4209222A1 (en) 2023-07-12
JP2017515812A (ja) 2017-06-15
DK3137094T3 (da) 2023-02-27
KR102506460B1 (ko) 2023-03-03
EP3137094A1 (en) 2017-03-08
CN106659736A (zh) 2017-05-10
US20220000908A1 (en) 2022-01-06
EP3137094B1 (en) 2022-12-07
AU2015254665A1 (en) 2016-11-10
US11857568B2 (en) 2024-01-02
US11065273B2 (en) 2021-07-20
US20170049810A1 (en) 2017-02-23
US20240148782A1 (en) 2024-05-09
CA2946931A1 (en) 2015-11-05
PT3137094T (pt) 2023-03-09
FI3137094T3 (fi) 2023-03-20

Similar Documents

Publication Publication Date Title
IL247085B (en) Methods for treating Alzheimer's disease
IL276315A (en) Donepezil preparations and a method for treating Alzheimer's disease
ZA201605341B (en) Methods of treating alzheimer's disease
IL266047A (en) Methods and preparations for the treatment of Fabry disease
EP3182989A4 (en) Methods and compositions for the prevention and treatment of disease
IL248592A0 (en) Treatment of Crohn's disease using delayed-release 6-mercaptofurin
SG11201705889VA (en) Prevention or Treatment of Uratic or Gouty Diseases
PL3137097T3 (pl) Leczenie i profilaktyka choroby Alzheimera (AD)
IL248935A0 (en) Diagnostic testing and treatment/prevention of Alzheimer's disease
PT3458045T (pt) Ebselen para uso no tratamento da doença de ménière
PT3137094T (pt) Tratamento e prevenção da doença de alzheimer (da)
IL254252A0 (en) History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease
PL3352742T3 (pl) Kompozycje zawierające triterpenoidy do leczenia choroby alzheimera i choroby parkinsona
HUE037501T2 (hu) Alzheimer-kór (AD) kezelése és megelõzése
IL251135A (en) A method for the synthesis of hydroxy-triglycerides and their use for disease prevention and treatment
ZA201801945B (en) Compositions and methods for the treatment of parkinson's disease
GB201622116D0 (en) Treatment of liver disease
GB201511453D0 (en) Treatment of alzheimer's disease
GB201621398D0 (en) Treatment of emt-associated disease
GB201504144D0 (en) Treatment of Parkinson's disease
AU2015904411A0 (en) Compositions and methods for the treatment of Alzheimer's disease
GB201518052D0 (en) Parkinson's disease treatment
GB201610906D0 (en) Treatment of cardiovascular disease
GB201504413D0 (en) Treatment of disease
HK1230506A1 (en) Treatment of crohn's disease with delayed-release 6-mercaptopurine